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Adherence to Highly Active Antiretroviral Therapy (HAART) is the main prognostic factor
associated with HIV disease progression and death.The aim was to evaluate the effective-
ness of a psycho-educational program to promote adherence to HAART in HIV patients. A
longitudinal study (n=102) over 9 months in an Infectious Diseases Hospital was carried
out. Adherence to HAART was measured with standardized scales and values of viral load.
Two groups were defined: adherents and non-adherents. In the latter, a psycho-educational
program was implemented and 6 months later measured adherence to HAART. Knowledge
about the infection, CD4 T lymphocytes and HIV-ribonucleic acid values were measured
before and after this program. The sample was predominantly male (70%), heterosexual
(78%), with a mean age of 49 (SD=12.7) years, and 48% of participants were not adhering
to HAART. After the program, non-adherence decreased to 21.6%. Knowledge about the
infection increased from 79 to 97%. A significant increase in CD4 T lymphocytes (mean
540–580) and a decrease in viral load (mean 5411–3052) were observed, the latter of sta-
tistical significance.This program seems to be feasible and efficient, improving adherence
to HAART.
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INTRODUCTION
HIV infection represents a significant cause of illness and death
worldwide (1). The patterns of infection and associated diseases
are continuously developing, with the emergence of new cases
occurring throughout the world. The main epidemiological fea-
ture is the prevalence and incidence of infection, varying from
place to place, as a consequence of numerous factors such as
lifestyle and behavior, social and economic development, acces-
sibility to health care, and the local epidemiological pattern (1,
2). Therefore, the treatment must be contextualized in a holistic
view of the individual, family, and community and must be under-
stood as a priority (1, 3, 4). Although a cure is not yet available,
there are drugs, which are highly effective in controlling the dis-
ease, the Highly Active Antiretroviral Therapy (HAART). HAART
has greatly contributed to improved survival and decreased mor-
bidity and mortality among individuals infected with HIV/AIDS
(5–9). In fact, HAART can reduce the rate of progression to AIDS
or death in 86% of cases (10). However, failure rates can occur,
because HAART reveals a wide variability in plasma concentra-
tions achieved (7). This variability may be due to several factors
including absorption, metabolism, clearance, drug interactions,
and the adherence to therapy (7, 11, 12). From this perspective,
it will be difficult to accurately predict the actual concentra-
tion that individuals will achieve. The effectiveness of HAART is
now unquestionable, but there are also known adverse effects and
toxicity that can manifest in the short or long term and that some-
times prevent the patient from adhering strictly to the therapeutic
regime (12–17). Inadequate antiretroviral drug adherence leads
to sub-therapeutic levels providing selective pressure and con-
sequently adding pharmacological resistance (18–21). The main
prognostic factor associated with disease progression and death
is non-therapeutic adherence, requiring compliance with 95%
of medication to achieve viral suppression and a stable preser-
vation of immune function (22–24). Its absence leads to public
health problems, since in addition to the lack of response to treat-
ment, resistance to antiretroviral treatment will emerge quickly,
which not only jeopardizes the future treatment regimens for the
patient, but also for others, due to contamination by strains already
resistant to drugs (25–27). Non-adherence is multifactorial and
differs between patients. Different studies show different factors
that influence therapeutic adherence. Socio-demographic factors
are not associated with adherence (28, 29). However, psycholog-
ical factors such as motivation, depression, and factors related
to social support, support of health services, and information
reveal a strong association with adherence to therapy (30–39).
The increased life expectancy achieved as a result of HAART may
have an impact on psychosocial and psychopathological reactions.
The emotional reaction to infection can assume different levels
and can change during the evolution of the disease (34). Nowa-
days, the patient no longer lives with the certainty of premature
death, but still feels the stigma of HIV infection (38, 40–42). Often
the sense of life being under threat is replaced by a continu-
ing reassessment of its meaning (43). Recent studies show that
HIV patients suffer a significant degree of psychological distress,
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FIGURE 1 | Flow chart.
manifested by a high prevalence of anxiety and depression (varying
between 22 and 34%, and 26 and 41%, respectively) (42, 44–46).
In terms of serious psychological symptoms, the literature shows
a high prevalence of suicidal ideation (47). There are still quite
frequent psychotic disorders in the advanced stages of the disease,
and disruptions arising from the use of drugs or alcohol (48).
Although patients now have new hope, stress, and emotional pain
become constant and consequently affect their ability to rebalance
and reintegrate their lives (49,50). HIV infection may lead the indi-
vidual to the destruction of their life goals, as well as absence of self-
control and autonomy. The feelings of loss and grief and a sense of
their new responsibilities are major stressors and threats to psycho-
logical well-being (49, 50). This infection is the cause of enormous
suffering and socio-economic consequences. Therefore, strategies
of psychological intervention to support therapeutic adherence
become essential, since the first treatment regimen is considered
the best opportunity for long-term control of viral replication (1,
21, 30, 51, 52). The commitment of all health professionals in
the promotion of adherence to antiretroviral therapy is essential,
using innovative intervention strategies and involving the patient
and family in their own treatment decisions (1, 21). One strategy
may be the implementation of interventions based on psycho-
educational programs (30, 53–56). In one of the studies (30), the
authors compared two interventions to increase HIV adherence,
one based on cognitive-behavioral, motivational interviewing, and
problem-solving techniques, and the other one on self-monitoring
strategies, such as pill-diaries. Both interventions led to improve-
ments in adherence at follow-up, with the first one showing more
rapid results. Balfour et al. (54) conducted a randomized con-
trolled trial with a psycho-educational program, verifying that
this intervention not only reduced depressive symptomatology,
but also enhanced HIV treatment by providing the preparation
for HAART.
Considering these prior results, the purpose of this study was to
evaluate the effectiveness of psycho-educational intervention con-
ducted in a Portuguese hospital specializing in infectious diseases,
in promoting adherence to HAART of HIV patients who were not
drug addicts.
MATERIALS AND METHODS
PARTICIPANTS
A sample of consecutive patients (n= 102) was selected in a central
hospital specializing in treating HIV patients in Portugal during
3 months (Figure 1). The use of illicit drugs was established as
an exclusion criterion, since patients with a history of substance
abuse already follow a specific program in this hospital, and as
inclusion criteria, to be able to answer the questionnaires and have
a basic level of education. Each patient received detailed informa-
tion about the study and after that their informed consent was
given and approval of the regional research ethics committee was
obtained. Socio-demographic and family characteristics, health
services use, and knowledge about the disease were assessed in
a structured interview. Clinical data were also collected, includ-
ing medication use, HIV-ribonucleic acid (HIV-RNA), and CD4
T lymphocytes values.
MEASURES
Perceived satisfaction with social support
The perceived satisfaction with social support was assessed with
the Scale of Satisfaction with Social Support (SSSS) (57). This
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scale aims to assess satisfaction with perceived social support in
adults. It is a self-assessment scale with 15 items, presented as a
set of statements, which are spread over four distinct domains,
namely “satisfaction with friends,” “intimacy,” “satisfaction with
family,” and “social activities.” The individuals must indicate the
extent to which they agree with each statement on a scale of five
ordinal positions, which are: “strongly agree,”“agree mostly,”“nei-
ther agree nor disagree,” “mostly disagree,” and “disagree totally.”
The “satisfaction with friends” domain evaluates satisfaction with
friendships and includes five items; the“intimacy”domain assesses
the perception of the existence of intimate social support and
includes four items; the “family satisfaction” domain assesses sat-
isfaction with family support and includes three items; and the
“social activities” domain assesses satisfaction with social activities
and includes three items.
In the original validation study (57), the principal components
analysis revealed the presence of four components, which explain
63.1% of the total variance. Globally, this instrument revealed
good psychometric properties, regarding internal consistency
(α= 0.85 for total, α= 0.64–0.83 for components), concurrent
and discriminant validity.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) (58, 59), was
designed by Snaith and Zigmond and it is used as a support to
clinicians for identification and recognition of emotional compo-
nents associated with physical illness. It is a scale that has been
shown to be useful in hospitals, primary health care, and psychi-
atric settings and is considered a good instrument for screening
anxiety and depression. It consists of two sub-scales, each one
with seven items, measuring anxiety and depression. Both sub-
scales are scored separately. The individual answers each item in
an ordinal scale of four positions (0–3). The scores for each sub-
scale range from 0 to 21. Scores are considered as follows:“normal”
between 0 and 7, “mild” between 8 and 10, “moderate” between
11 and 14, and “severe” between 15 and 21. In the present study,
the Portuguese version validated by Ribeiro et al. (60) was used.
The Portuguese version revealed good psychometric proprieties,
similar to the original one, as well as to the other adapted versions
in other languages.
CD4 T lymphocytes
A CD4 T lymphocytes count was performed by collecting blood
samples before and after implementation of the intervention pro-
gram. The samples were collected by nurses at the hospital where
the study occurred, using sterile vacuum tubes. The samples were
analyzed in a specialized laboratory (Instituto Ricardo Jorge, in
Lisbon) and the results were validated by a clinical hematologist.
HIV-ribonucleic acid
Levels of HIV-RNA in the blood were measured before and after
implementation of the intervention program by amplification of
viral RNA in plasma and by reverse transcriptase polymerase chain
reaction (PCR) method in real time. Analyses were performed at
the Instituto Ricardo Jorge in Lisbon. It was considered in this
study that the patient had suppressed viral load if HIV-RNA values
in the blood were less than 50 copies.
Patient’s knowledge related to HIV infection
A multiple-choice questionnaire was developed by the research
team to assess the knowledge that patients had in relation to HIV
infection. The questionnaire assesses issues like transmission, pre-
vention, and treatment and was administered at baseline and after
the psycho-educational intervention.
Adherence to HAART
Adherence to HAART was measured through the simplified Scale
for Detecting Problems of Adherence to Antiretroviral Therapy
(SDPAAT) (61). This is a dichotomous scale and comprises six
items. Each item with a positive response scored one point and
a negative response zero points. The total score is the sum of the
items (minimum one and maximum six points). The first two
questions of the scale must be positively answered in order to
consider the patient free of problems with adherence. If both are
negative, the degree of adherence is one, independent of the rest of
the scores. It is considered that a patient has no adherence problem
if they are rated between 5 and 6 points.
In the original validation study, the scale showed good psy-
chometric proprieties, namely related to sensitivity 0.93 (CI95%
0.78–0.99), specificity 0.70 (CI95% 0.51–0.84), and a likelihood
ratio of 3.08 (CI95% 1.28–7.39). The validation process for
the Portuguese population includes its administration to the
sample of the present study, after its independent translation
and back-translation process by bilingual Spanish–Portuguese
specialists.
PROCEDURES
The different measures were completed by patients. The main
outcomes considered were adherence to HAART, proportion of
incorrect answers about HIV infection, and values of CD4 and
HIV-RNA. These outcomes were reassessed 6 months after the first
intervention.
Patients classified as non-adherent to HAART (n= 49) were
submitted to a group intervention program, comprising two ses-
sions, sponsored by a specialist community health nurse. Each
patient was called by phone for each session. The sample of non-
adherents was divided into three groups with 12 members each
and one group with 13. All of them were questioned about their
availability at the time of contact. In the case of no response to
the first phone call, three further calls were made on different
days. Each session lasted 120 min. The sessions were developed in
the training room of the hospital on weekdays (Monday to Satur-
day), alternating between the morning and afternoon in order to
maximize the likelihood of patient attendance.
Implementation of the intervention program
The program was implemented by a specialist community health
nurse, experienced in community intervention programs, and was
based on a project methodology (62, 63). The two sessions were
implemented following a manual developed by the research team,
with objectives, subjects, strategies, and resources, based on Health
Education Action for groups with HIV infection and antiretroviral
therapy. An expository methodology with a theoretical and inter-
actional program, using multimedia (Powerpoint) was chosen. In
the first session, issues related to the pathogenesis of infection,
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prevention, and transmission were explained, as well as general
principles of antiretroviral medication and the importance of
adherence to therapy. During the presentation, the non-adherent
sample patients were encouraged to participate with questions and
suggestions. A second session consisted of an explanation about
patients’ problems and feelings, and the promotion of shared dif-
ficulties and experiences as well as their empowerment, through
discussion and problem solving. The topics were always diverse
and chosen by the patients, consisting of the marginalization and
prejudice that they often feel and the fear of colleagues and neigh-
bors on discovering their illness. Legal issues about bank loans
were discussed, once they identified this as an important problem.
Strategies were highlighted to minimize forgetting to take medica-
tion and to discuss the importance of the availability of reading
material about HIV/AIDS in the general population, in order to
destigmatise the disease. During the sessions, the promotion of a
calm and cozy environment was found to be important to develop
a therapeutic relationship. At the end of each intervention a syn-
thesis of the content of the discussion was carried out. During the
group sessions there was no resistance to patients’ participation
in the sessions due to the health problem in question. There was
however a need to ensure the complicity of all participants, as it
was a cohesive group, in which all were patients with HIV.
STATISTICAL ANALYSIS
The statistical analysis was performed with the Statistical Package
for the Social Sciences – SPSS® for Windows, version 17.0.
For the comparison of dependent or related groups, the para-
metric Student test for paired samples was used. When normality
of the distributions could not be assumed, the Wilcoxon non-
parametric test was used. Additionally, when appropriate, correla-
tion analyses between variables of interest were performed with the
Pearson correlation coefficient. The non-parametric chi-square
test was also used to verify the associations between the baseline
and final assessments and among other variables in the study. All
analyses assumed 95% confidence interval (95% CI, two-tailed).
For the validation of SSSS and in order to extract common fac-
tors from the interpretation of the items relating to this scale, an
exploratory factor analysis was performed (with varimax rotation)
to explore the behavior of the scale with this particular population.
Cronbach’s alpha was computed to assess the internal consistency
of the validated scale and its factors.
The validation of SDPAAT was performed by calculating its sen-
sitivity (ratio of non-adherents detected by SDPAAT and the true
non-adherents) and specificity (ratio between adherents detected
by SDPAAT and the true adherents).
Finally, to assess the significance of some variables on the likeli-
hood of adherence to HAART, the logistic regression method For-
ward: LR (64–66) was used. Variables like gender, anxiety, depres-
sion, regular monitoring at the health center, answers to perceived
needs, number of children, knowledge of the disease, admissions,
and number of medication doses per day were explored.
RESULTS
SOCIO-DEMOGRAPHIC CHARACTERISTICS
In the initial sample (n= 102), 70% of individuals were male and
had an average age of 49 (SD= 12.7). Most were unmarried (56%)
and almost all were Caucasian (97%). The majority were het-
erosexual (78%) and 70% had completed secondary education.
The most common (35%) professions were in the tertiary sector
(commerce, communications, health, and education).
FAMILY CHARACTERISTICS
In this study, 28% of patients lived alone. Approximately 65% had
children and 76% considered they spent enough time with their
family. Among the patients, 16% believed their health influenced
their relationship with their family, and in 70%, the diagnosis
of HIV was identified as the main event, which had disturbed the
family relationship. The majority believed they needed family sup-
port (88%), and that their spouse or partner was the best person
available to help.
CLINICAL CHARACTERISTICS
Table 1 shows that the entire sample was infected with HIV-1, and
the duration of infection was 7 years on average. About 28% of
patients were classified (Centers for Disease Control and Preven-
tion) as being in the AIDS stage and had a median of 344 CD4
T lymphocytes, and the majority had a viral load below 50 copies
(78%). The majority of the patients were taking medications twice
a day (67%),corresponding on average to four tablets per day. Most
subjects referred had no side effects to HAART (81%). Only about
19% had side effects such as fatigue, insomnia, nausea, and pain.
About 56% of the sample had already had to change treatment,
the main reasons being metabolic changes (50%) and resistance
to antiretroviral drugs (25%). Almost 30% had been hospitalized
between one and three times.
According to HADS, it was verified that 52.9% suffered from
anxiety, ranging in level from mild to severe (26.5% mild, 13.7%
moderate, and 12.7% severe). In relation to depression, 28.4%
scored for depression (15.7% mild, 9.8% moderate, and 2.9%
severe).
Through analysis of Table 2 it was concluded that accord-
ing to the SSSS, “Satisfaction with family” had a mean of
1.8 (SD= 1.2), “Satisfaction with friendships” a mean= 2.1
(SD= 1.2), “Intimacy” a mean= 2.4 (SD= 1.3), and “Social
Activities” a mean= 3.3 (SD= 1.2).
Regarding the SSSS factorial analysis, revealed the presence of
four components explaining 68.6% of the total variance in this
sample of HIV patients, namely Social Activities, which explained
35.1%, Satisfaction with friendships (14.6%), Satisfaction with
family (11.9%), and Intimacy (7.1%). All the factors found showed
good internal consistency (α= 0.83, 0.87, and 0.88, respectively),
except for Intimacy (α= 0.42), and all significantly correlated
(p< 0.01) with the SSSS total score.
The present study is part of the validation process of the Por-
tuguese version of SDPAAT, tested in the total sample of 102
patients. The scale showed a sensitivity of 0.61 (CI 95% 0.52–
0.71) and a specificity of 0.82 (CI 95% 0.74–0.89), when compared
with viral load values, used as gold-standard. Using the SDPAAT
scale, 48% (n= 49) of the total sample (n= 102) was classified
as non-adherent. In relation to SSSS dimensions and HADS sub-
scales, no significant differences were found in the mean values
between the group of adherent and non-adherent, classified by
SDPAAT.
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Table 1 | Clinical characteristics of sample.
(n=102) (%)
HIV-1 100
CDC: phase of AIDS 28
Time of infection ≥5 years 72
CD4 T lymphocytes
<200 8
201–350 28
>351 64
Viral load
≤50 78
>50 22
Tablets per day
Mean 3.8
Min./Max 1/11
Without ARV side effects 81
Hospitalized due to HIV 27
Anxiety (HADS)
Absent 47.1
Mild 26.5
Moderate 13.7
Severe 12.7
Depression (HADS)
Absent 71.6
Mild 15.7
Moderate 9.8
Severe 2.9
aMultiple-choice questions (number of valid cases, % of valid cases and total valid
cases).
Table 2 | Satisfaction with social support (SSSS) – 1st assessment.
(n=101) Mean (±SD) No. items Min. Max.
Satisfaction with family 1.85 (±1.16) 3 1 5
Satisfaction with friendships 2.09 (±1.22) 4 1 5
Intimacy 2.37 (±1.26) 2 1 5
Social activities 3.33 (±1.21) 6 1 5
INTERVENTIONAL PROGRAM
In the interventional program, it was found that 43% of non-
adherents to HAART participated in the first session, and 14.3%
in the second session. Of the non-adherents to HAART, 69 and
71% reported that their absence in the first and second ses-
sions, respectively, was due to work commitments or contact
difficulties.
Once the intervention program had been implemented, a sig-
nificant increase in the values of CD 4 lymphocytes was found
(p= 0.001) between the first (mean= 540.0, SD= 354.0) and final
moment (mean= 580.1, SD= 328.3) (Table 3).
In relation to the viral load outcome, despite the average reduc-
tion before and after the implementation of the intervention
program,this difference was not statistically significant (p= 0.509)
(Table 3).
Table 3 | Comparison of CD 4T lymphocytes and viral load before and
after the program.
N Mean (±SD) t p-Valuea
(n=102) CD 4
Initial/M0 102 540.02 (±353.99) −3.382 0.001
Final/M9 102 580.15 (±328.34)
(n=102)VIRAL LOAD
Initial/M0 102 5.410.73 (±32 011.36) 0.663 0.509
Final/M9 102 3.052.31 (±18 191.71)
aResults according to the Student’s t-test for two paired samples, with 95%
confidence.
In both groups, the CD4 lymphocytes significantly increased
between the first and second assessments (adherents, from 538 to
581, p< 0.01; non-adherents, from 360 to 416, p< 0.05).
Analyzing the data of Table 4, a significant association between
adherence before and after implementation of the intervention
program was observed (p= 0.002). In fact, most of the individuals
who had initially adhered to therapy remained until the end (91%).
After the implementation of the psycho-educational program,
65% of the initial non-adherent individuals became adherents
to HAART. In all samples, the adherence to HAART after the
implementation of the program increased from 52 to 78%.
In the present study, an additional analysis of the impact of
some variables described in the literature as predictors of adher-
ence to HAART was carried out. No variables were indepen-
dently associated with the adherence to HAART, although gender
(p= 0.054) and knowledge about infection (p= 0.051) almost
reached statistical significance.
DISCUSSION
This study was the first intervention developed with Portuguese
HIV patients, whose strategy for implementing the program con-
sisted in a combination of behavioral and educational approaches,
in a group intervention. The study suggests that the implemen-
tation of this psycho-educational program was effective in pro-
moting adherence to HAART and leads to significant gains in
the immune status of patients, especially in relation to CD4 T
lymphocytes levels. These results are in line with the findings
from previous studies [e.g., Ref. (30, 44, 45, 47, 48, 54)] that
also concluded psycho-educational interventions could enhance
adherence to HAART.
It was also observed in the present study that the implemen-
tation of the psycho-educational program significantly reduces
the average HIV-RNA. Also a reduction in viral load values was
observed, in spite of no statistical significance achieved. In rela-
tion to CD4 T lymphocytes, a statistically significant increase was
observed.
Regarding adherence to HAART, it was found that the group
of adherents continued to be adherents to HAART and the major-
ity of the non-adherent individuals became adherents after the
implementation of the psycho-educational program. Adherence
to HAART was assessed using a scale based on the immune sta-
tus of the patient, his attendance to collect his medication from
the pharmacy and his knowledge regarding medication. This
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Table 4 | Comparison of adherence to HAART between groups (adherents and non-adherents), at 1st and 2nd assessment.
1st Assessment (before the program)
Adherent Non-adherent Total p-Valuea
2nd Assessment (after the program) Adherent 48 (90.6%) 32 (65.3%) 80 (78.4%) 0.002
Non-adherent 5 (9.4%) 17 (34%) 22 (21.6%)
Total 53 (100%) 49 (100%) 102 (100%)
aAccording to the results of the chi-square with 95% confidence.
method was preferred over self-based assessment methods that
could overestimate adherence, leading to imprecise estimates (47).
With the implementation of this program it was also found
that patients’ knowledge about HIV infection, as assessed by the
number of right answers on the questionnaire, improved. There
was a significant decrease in the average number of wrong answers
after the implementation of the intervention compared to baseline
assessment.
It is important bearing in mind that viral suppression and
immunological stability, and consequently the minor risk of
opportunistic infections and malignancies depends on adherence
to HAART. To remain adherent to treatment, the patient avoids
or delays the potential resistance to HAART, thereby achieving
a more extensive range of alternative therapies to delay disease
progression. In that sense interventions with educational compo-
nents about the disease and its treatment, are gaining relevance by
showing effectiveness in improving adherence to medication.
Regarding the SSSS, the factor structure found in this study
was not similar to that obtained in the original study (57), with
three of the items regrouped in different factors. All the dimen-
sions of the scale showed good internal consistency, achieving
higher values than the original validation study, except for Inti-
macy. The extremely low value of Cronbach alpha related to the
last dimension, could be explained by the small number of items.
Also in accordance with the original study (57), the SSSS
revealed good discriminant validity, with statistically significant
correlations between the total and domains as well as between
items and domains.
The present study forms part of the validation process of
SDPAAT. Compared with the original study (61), the Portuguese
version of SDPAAT showed moderate sensitivity values and good
specificity. However, these values must account for some method-
ological heterogeneity such as gold-standard considered (viral load
values vs. pharmacy record about the medication delivered that
was used in the original study).
Although some studies [e.g., Ref. (30, 38, 39)] presented psy-
chological factors such as anxiety, depression and social support
associated with adherence to therapy, emphasized the importance
of exploring interventions to improve its diagnosis and treatment,
in the present study no differences were found in these domains
between adherent and non-adherent patients.
An aspect that may be relevant is the fact that before imple-
menting the program contact between the research team and the
patients was reduced. A continuing professional relationship that
would allow the consolidation of trust and empathy was crucial
for the aim of the program. These factors are essential when
trying to develop such interventions. The rigorous study of the
implementation and evaluation of intervention programs to pro-
mote adherence to HAART through psychological and educational
methodology in a group is imperative, given that in clinical prac-
tice the resources are few, and it is crucial to its effectiveness. In
this study, the methodology was developed using assessment scales
validated for the Portuguese population (SSSS and HADS).
Some limitations of the present work resulted from the lack of
a control group and the study’s experimental design.
Also it must be taken into consideration that these results may
have been influenced by the additional contact per se with the
health professional, when the assessments were performed. The
literature shows that the rates of adherence to intervention pro-
grams continue at a lower level in spite of innovative programs (40,
67). In this study, it was observed that patients participated with
interest in the sessions, above all in the first one. These patients
participated actively in the discussions. However, lower adherence
was found in the second session, perhaps because it coincided
with the start of the school year. Some patients reported having
work commitments. It is noteworthy that the majority of the study
population was professionally active and some of them resided in
a district outside the hospital area, which may explain their lack of
availability to attend the sessions.
Further studies should be conducted with randomized clinical
trials. It is essential that patients know the health professionals
and that the co-construction of knowledge is based on empa-
thy that is established between patient and professional. It is
important that health professionals assume the commitment to
foster targeted interventions with innovative models to promote
care (40, 68–71). Developing intervention projects in this area
is a continual challenge, especially for the health professionals
involved. This study, due to its innovative nature, is undoubt-
edly an incentive to develop strategies for ongoing support, with
efficiency in health promotion reflected in gains in the health of
these populations.
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